ELOXX PHARMACEUTICALS, INC. Long-Term Debt, Maturity, Year Five
ELOXX PHARMACEUTICALS, INC. (ELOX) had Long-Term Debt, Maturity, Year Five of $417.00 thousand as of 2019-09-30, per its 10-Q filed 2019-11-06.
Discontinued › Notes › Commitment and Contingencies › Long-Term Debt, Fiscal Year Maturity › Long-Term Debt, Maturity, Year Four and Five
us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFive · last filed 2019-11-06
- 2019-09-30: Long-Term Debt, Maturity, Year Five $417.00K.
- 2019-06-30: Long-Term Debt, Maturity, Year Five $417.00K.
- 2019-03-31: Long-Term Debt, Maturity, Year Five $420.00K.
| Period end | Long-Term Debt, Maturity, Year Five |
|---|---|
| 2019-09-30 | $417.00K 10-Q · filed 2019-11-06 |
| 2019-06-30 | $417.00K 10-Q · filed 2019-08-07 |
| 2019-03-31 | $420.00K 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Tevogen Inc. (TVGN) | United States | $0.049B |